2689 related articles for article (PubMed ID: 18787948)
21. Prognostic importance of the axillary lymph node ratio in autologous transplantation for high-risk stage II/III breast cancer.
Bolwell B; Andresen S; Pohlman B; Sobecks R; Goormastic M; Rybicki L; Bell K; Kalaycio M
Bone Marrow Transplant; 2001 Apr; 27(8):843-6. PubMed ID: 11477442
[TBL] [Abstract][Full Text] [Related]
22. Breast conservation after neoadjuvant chemotherapy for stage II carcinoma of the breast.
Schwartz GF; Meltzer AJ; Lucarelli EA; Cantor JP; Curcillo PG
J Am Coll Surg; 2005 Sep; 201(3):327-34. PubMed ID: 16125064
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant chemotherapy in stage III breast cancer.
Alassas M; Chu Q; Burton G; Ampil F; Mizell J; Li BD
Am Surg; 2005 Jun; 71(6):487-92. PubMed ID: 16044927
[TBL] [Abstract][Full Text] [Related]
24. Extracapsular extension in positive axillary lymph nodes in female breast cancer patients. Patterns of failure and indications for postoperative locoregional irradiation.
Stranzl H; Mayer R; Ofner P; Peintinger F; Prettenhofer U; Hackl A
Strahlenther Onkol; 2004 Jan; 180(1):31-7. PubMed ID: 14704842
[TBL] [Abstract][Full Text] [Related]
25. T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy.
Garg AK; Strom EA; McNeese MD; Buzdar AU; Hortobagyi GN; Kuerer HM; Perkins GH; Singletary SE; Hunt KK; Sahin A; Schechter N; Valero V; Tucker SL; Buchholz TA
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):138-45. PubMed ID: 15093909
[TBL] [Abstract][Full Text] [Related]
26. Long-term outcomes in stage IIIB breast cancer patients who achieved less than a pathological complete response (Ionta MT; Atzori F; Deidda MC; Pusceddu V; Palmeri S; Frau B; Murgia M; Barca M; Minerba L; Massidda B
Oncologist; 2009 Nov; 14(11):1051-60. PubMed ID: 19897535
[TBL] [Abstract][Full Text] [Related]
27. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
[TBL] [Abstract][Full Text] [Related]
28. [Clinical features and prognostic factors of small breast cancer with multiple axillary lymph node metastasis].
Liao YQ; Xu BH
Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):615-8. PubMed ID: 18210884
[TBL] [Abstract][Full Text] [Related]
29. Lymph node counts and ratio in axillary dissections following neoadjuvant chemotherapy for breast cancer: a better alternative to traditional pN staging.
Chen S; Liu Y; Huang L; Chen CM; Wu J; Shao ZM
Ann Surg Oncol; 2014 Jan; 21(1):42-50. PubMed ID: 24013900
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant chemotherapy in invasive breast cancer results in a lower axillary lymph node count.
Bélanger J; Soucy G; Sidéris L; Leblanc G; Drolet P; Mitchell A; Leclerc YE; Beaudet J; Dufresne MP; Dubé P
J Am Coll Surg; 2008 Apr; 206(4):704-8. PubMed ID: 18387477
[TBL] [Abstract][Full Text] [Related]
31. Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer.
Honkoop AH; Luykx-de Bakker SA; Hoekman K; Meyer S; Meyer OW; van Groeningen CJ; van Diest PJ; Boven E; van der Wall E; Giaccone G; Wagstaff J; Pinedo HM
Oncologist; 1999; 4(2):106-11. PubMed ID: 10337380
[TBL] [Abstract][Full Text] [Related]
32. Patients with t1 to t2 breast cancer with one to three positive nodes have higher local and regional recurrence risks compared with node-negative patients after breast-conserving surgery and whole-breast radiotherapy.
Truong PT; Jones SO; Kader HA; Wai ES; Speers CH; Alexander AS; Olivotto IA
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):357-64. PubMed ID: 18676091
[TBL] [Abstract][Full Text] [Related]
33. [Clinical analysis of resectable breast cancer: a report of 6 263 cases].
Yang MT; Rong TH; Huang ZF; Zeng CG; Long H; Fu JH; Lin P; Wang X; Wang SY; Wang X; Tang J
Ai Zheng; 2005 Mar; 24(3):327-31. PubMed ID: 15757535
[TBL] [Abstract][Full Text] [Related]
34. Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer.
Cox CE; Cox JM; White LB; Stowell NG; Clark JD; Allred N; Meyers M; Dupont E; Furman B; Minton S
Ann Surg Oncol; 2006 Apr; 13(4):483-90. PubMed ID: 16523361
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of axillary microresiduals after neoadjuvant chemotherapy in breast cancer patients with cytologically proven metastases.
Sakakibara M; Nagashima T; Kadowaki M; Onai Y; Fujimori T; Yokomizo J; Suzuki H; Fushimi K; Nakatani Y; Miyazaki M
Ann Surg Oncol; 2009 Sep; 16(9):2470-8. PubMed ID: 19588201
[TBL] [Abstract][Full Text] [Related]
36. Regional nodal recurrence in the management of breast cancer patients with one to three positive axillary lymph nodes. Outcome of patients following tangential irradiation without a separate nodal field.
Stranzl H; Peintinger F; Ofner P; Prettenhofer U; Mayer R; Hackl A
Strahlenther Onkol; 2004 Oct; 180(10):623-8. PubMed ID: 15480510
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
[TBL] [Abstract][Full Text] [Related]
38. Factors predictive of having four or more positive axillary lymph nodes in patients with positive sentinel lymph nodes: implications for selection of radiation fields.
Shahar KH; Hunt KK; Thames HD; Ross MI; Perkins GH; Kuerer HM; Strom EA; McNeese MD; Meric F; Schechter NR; Sahin AA; Middleton LP; Buchholz TA
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1074-9. PubMed ID: 15234041
[TBL] [Abstract][Full Text] [Related]
39. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy.
Low JA; Berman AW; Steinberg SM; Danforth DN; Lippman ME; Swain SM
J Clin Oncol; 2004 Oct; 22(20):4067-74. PubMed ID: 15483018
[TBL] [Abstract][Full Text] [Related]
40. The role of irradiation of the internal mammary lymph nodes in high-risk stage II to IIIA breast cancer patients after high-dose chemotherapy: a prospective sequential nonrandomized study.
Stemmer SM; Rizel S; Hardan I; Adamo A; Neumann A; Goffman J; Brenner HJ; Pfeffer MR
J Clin Oncol; 2003 Jul; 21(14):2713-8. PubMed ID: 12860949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
